ReviewVisceral medicine2017
Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.
Review in Visceral medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.Oncology · 2021Trial
- Primary tumor resection improves survival in colon cancer patients with unresectable liver only metastases.Discover oncology · 2025Article
- Assessment of non-tumor liver parenchyma damage in advanced gastric cancer treatment with transarterial infusion chemotherapy: a study using imaging and hepatic injury indicators.Frontiers in oncology · 2025Article
- Article
- Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study.BMC gastroenterology · 2022Article
- Survival outcomes in unresectable metastatic rectal cancer patients after both primary site resection and chemoradiotherapy: a SEER-based observational study.Translational cancer research · 2022Article
- Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis.Frontiers in oncology · 2022Article
- Progress toward improving outcomes in patients with cholangiocarcinoma.Current treatment options in gastroenterology · 2021Article
- The evolution of interventional oncology in the 21st century.The British journal of radiology · 2020Review
- A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks.The Journal of surgical research · 2020Article
- Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review.Cancer management and research · 2020Article
- Aberrant arc between the common hepatic artery and a replaced right hepatic artery resulting in misperfusion in a patient with a hepatic arterial infusion pump.Surgical and radiologic anatomy : SRA · 2019Article
- Dietary glycine decreases both tumor volume and vascularization in a combined colorectal liver metastasis and chemotherapy model.International journal of biological sciences · 2019Article
- Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells.Oncology letters · 2018Article
- Oligometastases of Gastrointestinal Cancer Origin.Visceral medicine · 2017Article
- Outcomes of Patients With Colorectal Liver Metastasis in the Developing World: Is Liver Transplantation for Unresectable Liver Metastasis, the Next Logical Step?Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe liver is the most common site for metastases from colorectal cancer (CRC) with the majority of these patients having unresectable disease.
methodsThis is a retrospective review of studies using hepatic arterial infusion (HAI) therapy to treat liver metastasis from CRC. A PubMed search of randomized controlled trials and retrospective studies from 2006 to present was conducted using the search terms 'hepatic arterial infusion (HAI) therapy', 'colorectal cancer', and 'treatment of liver metastases'.
resultsThe first randomized studies comparing HAI to systemic therapy with 5-fluorouracil/leucovorin produced significantly higher response rates of 41 versus 14%. Systemic therapy has improved with the addition of irinotecan and oxaliplatin; however, the responses with HAI and these modern agents have also increased, with responses as high as 80%. For patients with wild-type KRAS, HAI and systemic therapy produced a median survival of 68 months. In patients with refractory disease, response rates are in the 30% range with a median survival of 20 months. Adjuvant HAI after liver resection has shown an increase of hepatic disease-free survival and overall disease-free survival when compared to systemic therapy alone in three of four randomized trials. A recent update of the adjuvant trials after liver resection at Memorial Sloan Kettering Cancer Center has shown a 5-year survival of 78%.
conclusionHAI therapy has a role in treating hepatic metastases from CRC in both the resectable and unresectable setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.